Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 33 Novo Nordisk has a strong leadership position within the growing diabetes care market DKK billion 500 Global diabetes care market by treatment class OAD GLP-1 Insulin value market share Global diabetes care Novo Nordisk Sanofi - Eli Lilly Novartis AstraZeneca Merck - Takeda Boehringer Ingelheim 28% 400 300 200 100 0 Aug 2008 J&J - Total market: CAGR¹ 15.3% Injectables: CAGR¹ 18.2% 30% 25% 20% 35.1%¹ 15% 16.0%¹ 10% 5% 11.8%¹ 0% Aug 2018 Aug 2008 1 CAGR for 10-year period OAD: Oral anti-diabetic Source: IQVIA MAT Aug, 2018 value figures changing diabetes Source: IQVIA MAT Aug, 2018 value figures Aug 2018 novo nordisk

View entire presentation